Endotoxemia, nutrition, and cardiometabolic disorders
- PMID: 25326898
- DOI: 10.1007/s00592-014-0662-3
Endotoxemia, nutrition, and cardiometabolic disorders
Abstract
Aims: Circulating lipopolysaccharides (LPSs), associated with both infection and inflammation, may arise from the gastrointestinal tract microbiota, and the levels may be affected by daily nutrition. We investigated whether nutrient intake affects the association of serum LPS activity with prevalent obesity, metabolic syndrome (MetS), diabetes, and coronary heart disease (CHD) and with the risk of incident CHD events.
Methods: The nutrition cohort (n = 2,452, mean age ± SD, 52.2 ± 10.1 years) of the FINRISK 1997 Study was followed up for 10 years. Information on macronutrient intake at baseline was collected from 24-h dietary recall. Serum endotoxin activities were determined by the Limulus amebocyte lysate assay.
Results: LPS activity was associated directly with the total energy intake and indirectly with carbohydrate intake in lean, healthy subjects. High LPS was significantly associated with prevalent obesity, MetS, diabetes, and CHD events, independently of established risk factors, CRP, and total energy or nutrient intake. The ORs (95 % CI) were 1.49 (1.21-1.85, p < 0.001, Q2-4 vs. Q1) for obesity, 2.56 (1.97-3.32, p < 0.001, Q2-4 vs. Q1) for MetS, 1.94 (1.06-3.52, p = 0.031, Q2-4 vs. Q1) for CHD, and 1.01 (1.00-1.01, p = 0.032, LPS unit) for diabetes. In the follow-up, high LPS was significantly associated with the risk of CHD events with a hazard ratio of 1.88 (1.13-3.12, p = 0.013, Q2-4 vs. Q1). This association was independent of baseline established risk factors, diet, obesity, MetS, and diabetes.
Conclusion: A high serum LPS activity is strongly associated with cardiometabolic disorders, which supports the role of bacterial infections and immune response in their etiology.
Similar articles
-
Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population.Metabolism. 2010 May;59(5):628-34. doi: 10.1016/j.metabol.2009.09.006. Epub 2009 Nov 14. Metabolism. 2010. PMID: 19913840
-
Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease.Obesity (Silver Spring). 2012 Apr;20(4):842-8. doi: 10.1038/oby.2011.136. Epub 2011 Jun 2. Obesity (Silver Spring). 2012. PMID: 21633402
-
Postprandial Endotoxemia Linked With Chylomicrons and Lipopolysaccharides Handling in Obese Versus Lean Men: A Lipid Dose-Effect Trial.J Clin Endocrinol Metab. 2015 Sep;100(9):3427-35. doi: 10.1210/JC.2015-2518. Epub 2015 Jul 7. J Clin Endocrinol Metab. 2015. PMID: 26151336 Clinical Trial.
-
Prognostic interactions between cardiovascular risk factors.Dan Med J. 2014 Jul;61(7):B4892. Dan Med J. 2014. PMID: 25123126 Review.
-
Metabolic endotoxemia and diabetes mellitus: A systematic review.Metabolism. 2017 Mar;68:133-144. doi: 10.1016/j.metabol.2016.12.009. Epub 2016 Dec 18. Metabolism. 2017. PMID: 28183445 Review.
Cited by
-
Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia.Microbiome. 2024 Oct 4;12(1):192. doi: 10.1186/s40168-024-01901-1. Microbiome. 2024. PMID: 39367431 Free PMC article.
-
The Effect of the Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53 Combination (BN-202M) on Body Fat Percentage Loss in Overweight Individuals: A Randomized, Double-Blind, Placebo-Controlled Study.Nutrients. 2024 Jun 23;16(13):1993. doi: 10.3390/nu16131993. Nutrients. 2024. PMID: 38999741 Free PMC article. Clinical Trial.
-
The Effect of Enteric-Derived Lipopolysaccharides on Obesity.Int J Mol Sci. 2024 Apr 13;25(8):4305. doi: 10.3390/ijms25084305. Int J Mol Sci. 2024. PMID: 38673890 Free PMC article. Review.
-
The individual response to antibiotics and diet - insights into gut microbial resilience and host metabolism.Nat Rev Endocrinol. 2024 Jul;20(7):387-398. doi: 10.1038/s41574-024-00966-0. Epub 2024 Mar 14. Nat Rev Endocrinol. 2024. PMID: 38486011 Review.
-
Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder.Front Immunol. 2024 Jan 26;15:1321395. doi: 10.3389/fimmu.2024.1321395. eCollection 2024. Front Immunol. 2024. PMID: 38343539 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
